Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q2 FY24 Earnings Presentation
38 slides from Supriya Lifescience's earnings presentation, Nov 7, 2023
Slide 1: Investor Presentation filing letter to BSE and NSE
Date: November 7, 2023 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street, Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543434 Scrip Symbol: SUPRIYA Dear Sir/Madam, Subject: Investor Prese
Slide 2: Earnings Presentation Q2FY24
Earnings Presentation Q2FY24
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Table of Contents
TABLE OF CONTENTS Sustainability 1. Q2FY24 Highlights Growth 2. Company Overview 3. Historical Financial Performance Profitability 4. Future Outlook
Slide 5: Q2 FY24 Highlights
Q2 FY24 Highlights
Slide 6: CMD's Message
CMD’s Message “At Supriya we believe that accessible, affordable and effective healthcare is a fundamental human right and to this effect – especially in a country like ours, I’m pleased to announce lately the Company has signed two agreements with Kalinga Institute of Technology for development of
Slide 7: Q2FY24 Highlights: Regional Performance
Q2FY24 Highlights (in INR mn) Revenue EBITDA PBT PAT Quarterly Rs. 1400.9 mn Rs. 317.5 mn Rs. 297.8 mn Rs. 238.8 mn 24.9 % YoY 11.2 % YoY 8.6 % YoY 41.6 % YoY Business Mix Revenue Contribution – By Region Regional Performance 47% 44% 41% Q2FY23 35% 34% Q1FY24 29% Q2FY24 11% 10% 13% 9% 8% 6% 4% 5% 4%
Slide 8: H1FY24 Highlights: Regional Performance
H1FY24 Highlights (in INR mn) Revenue EBITDA PBT PAT Half- Yearly Rs. 2721.2 mn Rs. 759.8 mn Rs. 724.2 mn Rs. 524.0 mn 27.4 % YoY 27.0 % YoY 25.8 % YoY 24.4 % YoY Business Mix Revenue Contribution – By Region Regional Performance 38% 39% 32% H1FY23 H1FY24 24% 23% 13% 11% 8% 7% 5% Asia Europe LAC Nor
Slide 9: Q2 & H1 FY24 Highlights Y-o-Y
Q2 &H1 FY24 Highlights (in INR mn) Revenue EBITDA PBT PAT +27% +26% +24% +27% 2,721.1 759.8 724.2 524.0 2,135.3 598.1 575.5 421.1 +25% +11% +42% +9% 1,400.9 1,121.7 317.5 297.8 238.8 285.6 274.2 168.6 Y-o-Y H1FY23 H1FY24 Q2FY23 Q2FY24 H1FY23 H1FY24 Q2FY23 Q2FY24 H1FY23 H1FY24 Q2FY23 Q2FY24 H1FY23 H1
Slide 10: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy Performance of the Therapeutic Areas 56% Q2FY23 Q2FY24 50% 13% 11% 12% 10% 7% 8% 6% 2% 2% 2% Analgesic/Anesthetic Anti-histamine Vitamins Anti-Asthmatic Anti-allergic Anti-malarial 9 Q2FY24 Earnings Presentation
Slide 11: Q2 & H1 FY24 Profit & Loss Statement
Q2 & H1 FY24 Profit & Loss Statement Particulars (in INR mn) Q2 FY24 Q2 FY23 Y-o-Y Q1 FY24 Q-o-Q H1 FY24 H1 FY23 Y-o-Y Revenue from Operations 1400.9 1121.7 25% 1,320.2 -2% 2721.2 2135.3 27% Cost of Materials Consumed 507.0 424.9 475.3 982.3 850.8 Changes in Inventories of Finished Goods and Work in
Slide 12: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities Particulars (in INR mn) Sep 23 Mar 23 Particulars (in INR mn) Sep 23 Mar 23 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Property, plant and equipment 2514.8 2,551.2 (i) Equity share capital 161.0 161.0 (ii) Right to Use Asset 50.7 53.2 (ii)
Slide 13: Summary Statement of Cashflow
Summary statement of Cashflow Particulars (in INR mn) Sep 23 Sep 22 Cash Flow from Operating Activities Profit before Tax 724.2 575.6 Adjustment for Non-Operating Items 39.8 22.7 Operating Profit before Working Capital Changes 764.0 598.3 Changes in Working Capital 27.9 -548.4 Cash Generated from Op
Slide 14: Company Overview
Company Overview
Slide 15: Business Overview
Business Overview Approved facility with Diversified operations Largest exporter of strong IP Niche product basket of Chlorpeniramine with presence in Maleate, Ketamine 38 APIs 86 countries Hydrochloride and Salbutamol Sulphate from India 15 DMFs with USFDA Manufacturing facility spread across React
Slide 16: Journey So Far
Journey So Far 2008 2009 2010 2011 2013 2014 Incorporation & Started CEP granted for IDL granted for COFEPRIS and USFDA approval conversion from production of Chlorphenamine Chlorphenamine KFDA granted; IDL a partnership Ketamine Maleate Maleate approval granted granted for firm to a public hydrochl
Slide 17: Company Differentiators
Company Differentiators Significant scale with leadership position across key & niche products Backward integrated business model Geographically diversified revenues with a global presence across 86 countries Advanced manufacturing and research and development capabilities Experienced senior managem
Slide 18: Backward Integrated Business Model
Backward Integrated Business Model Cost-competitive Supply Security Low Price Risk In-House Processes Structure Steady supply of Protection against Less Dependence On External Increasing margins essential raw materials market fluctuations Parties Integrated business model helped us grow revenue and
Slide 19: Diversified Geographic Presence
Diversified Geographic Presence • For key products we are seeing good traction in untapped regulated markets of North America • For Anaesthetic therapy 3 ANDA projects have been initiated and we are also working on ANDA projects for Anti Hypertensive and Vitamins Presence in 86+ Countries Across Glo
Slide 20: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence Significant export presence, with low dependence on a specific geography … with customer concentration Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations 77.0% 76.0% 80.0% 47% 45% 72.0% 40%
Slide 21: Advanced Manufacturing and R&D Capabilities
Advanced Manufacturing and R&D Capabilities 4 7 597 KL 23,806 sq.mt. Manufacturing blocks Clean Reactor Land segregated therapy wise rooms capacity area ✓ Well delineated areas for R&D, quality control (chemical microbiology), quality assurance, dedicated areas for Scaled up Manufacturing Facilities
Slide 22: R&D Capabilities
R&D Capabilities Supported by R&D driven mindset 15* DMFs 3* Process Patent DSIR approved 9* Filed in India facility CEPs ✓ The Company has a DSIR approved R&D facility in Parshuram Lote, Maharashtra. ✓ Team of 26 scientists* primarily focused across the value chain of API process development ✓ Supr
Slide 23: Complex Chemistries & Reaction
Complex Chemistries & Reaction Focus on uniform manufacturing standards to achieve standardised product quality across markets High vacuum distillations … across varied class of reactions Ability to handle complex chemistries.. Cyclisation Grignard reaction ✓ Simple to highly complex chiral centre m
Slide 24: Recognized by Key Regulatory Bodies
Recognized by Key Regulatory Bodies 23 Q2FY24 Earnings Presentation
Slide 25: Number of API's Under Pipeline
Number of API’s Under Pipeline API’s Under Pipeline Status USDMF’s 15 API’s Submitted CEP 9 API’s Granted USDMF 4 API Submission Under Progress CEP 1 API’s Assessment Under Progress CEP 4 API’s Submission Under Progress 24 Q2FY24 Earnings Presentation
Slide 26: Awards & Accreditation
Awards & Accreditation 2009 2010 2016 2017 2019 Certificate of Excellence for Special Recognition National Award Export House for the Year for Export House for the Year for Outstanding Export outstanding Export Performance in for Research and Development 2015-16 awarded by Directorate of 2016-17 awa
Slide 27: Key Management Team
Key Management Team Satish Wagh Saloni Wagh Shivani Wagh Rajeev Jain Krishna Raghunathan Chairman & MD Whole-time Director Whole-time Director Chief Executive Officer Chief Financial Officer • B.Sc. from R.D National College and • Bachelor’s degree in management • Master of Business Administration •
Slide 28: Historical Financial Performance
Historical Financial Performance
Slide 29: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance Robust revenue growth … Capex Spend … and, focus on profitability +13.3% EBITDA 5,300.5 1,078 PAT +17.8% 4,609.4 949 2,140 3,911.9 1,732 3,195.4 1,518 2,801.0 1,236 1,289 1,063 899 670 734 179 394 53 94 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19
Slide 30: Working Capital Break-up
Working Capital Break-up Inventory Receivables 233 73 206 68 63 61 172 53 130 76 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Payables Net Working Capital 78 79 235 75 194 196 59 49 105 67 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 No of days 29 Q2FY24 Earnings Presentation
Slide 31: Summary Statement of Profit and Loss
Summary Statement of Profit and Loss Particulars (in INR mn) FY23 FY22 FY21 Total Revenue 4,609.4 5,300.5 3,912.4 Cost of Materials Consumed 1,873.2 1,988.3 1,405.7 Purchase of Traded Goods - - - Changes in Inventories of Finished Goods and Work in Progress -65.1 -30.3 -124.5 Gross Profit 2,801.3 3,
Slide 32: Summary Statement of Assets and Liabilities
Summary Statement of Assets and Liabilities Particulars (in INR mn) Mar 23 Mar 22 Mar 21 Particulars (in INR mn) Mar 23 Mar 22 Mar 21 ASSETS EQUITY AND LIABILITIES Non-current assets EQUITY (i) Equity share capital 161.0 161.0 146.4 (i) Property, plant and equipment 2,551.2 1,824.7 969.5 (ii) Other
Slide 33: Summary Statement of Cashflow
Summary statement of Cashflow (in INR mn) Particulars (in INR mn) FY23 FY22 FY21 Cash Flow from Operating Activities Profit before Tax 1,234.9 2,072.5 1,673.9 Adjustment for Non-Operating Items 72.0 68.7 53.1 Operating Profit before Working Capital Changes 1,306.8 2,141.2 1,727.0 Changes in Working
Slide 34: Future Outlook
Future Outlook
Slide 35: Future Outlook
Future Outlook Two new R&D centres • The future of company lies in R&D, initiated the process of setting up enhanced R&D facility 1. The R&D lab at Lote Parshuram spread across 800 Sqm with 20 fume hoods is now commissioned and in operation. In this lab along with lifecycle management and backward i
Slide 36: Future Outlook
Future Outlook CMO/CDMO space • Company understands large scale special chemical manufacturing and has experience in handling hazardous complex process chemistry. • Initiated discussion with various companies ranging from big pharma to innovator companies to work as a partner for supplying products
Slide 37: Glossary
Glossary • API – Active Pharmaceutical Intermediates • DMF – Drug Master File • CEP – Certificate of Sustainability • USFDA – US Food And Drug Administration • EDQM – European Directorate for the Quality of Medicines & HealthCare • IDL – Import Drug Licence of China • KFDA – Korea Medical Device Reg
Slide 38: Thank You!
Thank You! Company : Investor Relations Advisors : Orient Capital (a division of Link Group) Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Irfan Raeen +91 97737 78669 Mr. Krishna Raghunathan - Chief Financial Officer irfan.raeen@linkintime.co.in cfo@supriyalifescience.com Mr. Ronak Jain